Avinoam Kadouri
Corporate Officer/Principal chez Weizmann Institute of Science
Profil
Avinoam Kadouri is the founder of Bonus Biogroup Ltd.
which was founded in 1981.
He held the title of Chief Technology Officer from 1981 to 2016.
Currently, he is a Professor at Weizmann Institute of Science.
In the past, he held the position of Chairman at The European Association for Bioindustries and Animal Cell Technology Industrial Platform.
He also held the position of Director-Technology Development at EMD Serono, Inc. and Uni Targeting Research AS.
Additionally, he held the position of Director-Worldwide Process Development at Serono International SA.
Postes actifs de Avinoam Kadouri
| Sociétés | Poste | Début |
|---|---|---|
| Weizmann Institute of Science | Corporate Officer/Principal | - |
Anciens postes connus de Avinoam Kadouri
| Sociétés | Poste | Fin |
|---|---|---|
| BONUS BIOGROUP LTD. | Fondateur | 01/09/2016 |
| The European Association for Bioindustries | Président | - |
| Animal Cell Technology Industrial Platform | Président | - |
| Serono International SA | Corporate Officer/Principal | - |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Directeur Technique/Scientifique/R&D | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BONUS BIOGROUP LTD. | Health Technology |
| Entreprise privées | 5 |
|---|---|
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Uni Targeting Research AS
 Uni Targeting Research AS BiotechnologyHealth Technology Uni Targeting Research AS is a holding company that provides the biopharmaceutical industry with tools and services for mammalian cell-line based development procedures and production processes. It offers upstream solutions to reduce complementary deoxyribonucleic acid and mammalian cell-line based timelines and increase protein production yields. Its technology enables both enhanced synthesis/secretion of naturally secreted proteins, and secretion of intracellular proteins. Its services include vector improvement, tailor-made vectors, and tool proteins. The company was founded by Ian Fraser Pryme, John E. Hesketh, Albert Tauler, and Beate Stern in 2001 and is headquartered in Bergen, Norway. | Health Technology |
| The European Association for Bioindustries | |
| Serono International SA | |
| Animal Cell Technology Industrial Platform |
